Goldman Sachs
CSCI

Goldman Sachs’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Goldman Sachs’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-845
Closed -$63K – 6747
2021
Q3 		$63K Sell
845
-826
-49% -$58.7K ﹤0.01% 6001
2021
Q2 		$147K Buy
+1,671
New +$159K ﹤0.01% 5855
2014
Q3 		– Sell
-2
Closed -$18K – 7289
2014
Q2 		$18K Buy
+2
New +$22.3K ﹤0.01% 6889

Other funds holding CSCI

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs's CSCI Position: Q4 2021 in Review

Goldman Sachs sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q4 2021, closing a stake of 845 shares — an estimated $63K sold.

Goldman Sachs first reported a position in CSCI in Q2 2014 and held it in 3 quarters. The position peaked at $147K in Q2 2021. 29 funds tracked by Wall St. Rank hold CSCI as of Q4 2021.

  • Goldman Sachs reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Goldman Sachs sold 845 COSCIENS Biopharma Inc. Common Stock shares in Q4 2021, an estimated $63K.
  • Goldman Sachs first reported a position in COSCIENS Biopharma Inc. Common Stock in Q2 2014 and held it in 3 quarters.
  • Goldman Sachs's COSCIENS Biopharma Inc. Common Stock position peaked at $147K in Q2 2021.
  • 29 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q4 2021.

Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.